Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 23;13:7907. doi: 10.1038/s41467-022-35590-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Experimental strategy to study the beneficial effect of MT1-MMP inhibition on SARS-CoV-2 infection in aged mice. b The level of plasma ACE2 in 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 was detected by western blotting (n = 3 for IgG control; n = 3 for 3A2). c The viral loads in the lungs (left) and tracheas (right) from 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 were quantified by qPCR analyses of the SARS-CoV-2 viral genes (n = 5 for IgG control; n = 6 for 3A2). d Immunostaining of SARS-CoV-2 Nucleocapsid Protein (NP) (green) in lung sections of 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2. (n = 5 for IgG control; n = 6 for 3A2) Scale bar: 20 μm. e, f Survival rate and weight changes in 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 (n = 5 for IgG control; n = 6 for 3A2). g Histological examination of lung sections from 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 by hematoxylin and eosin staining (n = 5 for IgG control; n = 6 for 3A2) (Scale bar: 20 μm). h Summary histology scores determined in the lung tissues from 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 (n = 5 for IgG control; n = 6 for 3A2). Data are means ± S.E.M. of three independent repeats. Statistical analyses were performed by unpaired two-tailed t-test for (c, h); one way ANOVA for (f). Source data are provided as a Source Data file.